• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循证医学:掌腱膜挛缩症的治疗选择:切开、切除与溶解

Evidence-Based Medicine: Options for Dupuytren's Contracture: Incise, Excise, and Dissolve.

作者信息

Denkler Keith A, Vaughn Carolyn J, Dolan Estelle L, Hansen Scott L

机构信息

San Francisco, Calif.

From the Division of Plastic Surgery, University of California, San Francisco.

出版信息

Plast Reconstr Surg. 2017 Jan;139(1):240e-255e. doi: 10.1097/PRS.0000000000002857.

DOI:10.1097/PRS.0000000000002857
PMID:28027258
Abstract

LEARNING OBJECTIVES

After studying this article, the participant should be able to: 1. Understand updates in the basic science, epidemiology, and treatment of Dupuytren's disease. 2. Understand treatment with needle aponeurotomy, collagenase, and fasciectomy. 3. Understand advanced needle techniques for Dupuytren's contracture. 4. Understand the safety and effectiveness of a new treatment, collagenase.

SUMMARY

The literature on Dupuytren's disease encompasses many specialties. Its treatment is generally by perforating, excising, or dissolving the affected tissues. This article reviews the changing understanding of this disease and treatment options.

摘要

学习目标

在研读本文后,参与者应能够:1. 了解掌腱膜挛缩症的基础科学、流行病学及治疗方面的最新进展。2. 了解针式腱膜切开术、胶原酶及筋膜切除术的治疗方法。3. 了解掌腱膜挛缩症的先进针刺技术。4. 了解一种新治疗方法——胶原酶的安全性和有效性。

总结

关于掌腱膜挛缩症的文献涵盖多个专业领域。其治疗通常是通过对受影响组织进行穿孔、切除或溶解。本文回顾了对该疾病及治疗选择不断变化的认识。

相似文献

1
Evidence-Based Medicine: Options for Dupuytren's Contracture: Incise, Excise, and Dissolve.循证医学:掌腱膜挛缩症的治疗选择:切开、切除与溶解
Plast Reconstr Surg. 2017 Jan;139(1):240e-255e. doi: 10.1097/PRS.0000000000002857.
2
Cost-effectiveness in the management of Dupuytren's contracture. A Canadian cost-utility analysis of current and future management strategies.掌腱膜挛缩症管理的成本效益。加拿大当前和未来管理策略的成本效益分析。
Bone Joint J. 2013 Aug;95-B(8):1094-100. doi: 10.1302/0301-620X.95B8.31822.
3
A single-centre cost comparison analysis of collagenase injection versus surgical fasciectomy for Dupuytren's contracture of the hand.手部挛缩性杜普伊特伦氏病中胶原酶注射与手术筋膜切开术的单中心成本比较分析。
J Plast Reconstr Aesthet Surg. 2014 Mar;67(3):368-72. doi: 10.1016/j.bjps.2013.12.030. Epub 2014 Jan 4.
4
Dupuytren's Contracture: An Evidence Based Review.掌腱膜挛缩症:基于证据的综述
Ann Plast Surg. 2018 Dec;81(6S Suppl 1):S97-S101. doi: 10.1097/SAP.0000000000001607.
5
Cost Comparison of Collagenase Clostridium Histolyticum and Fasciectomy for Treatment of Dupuytren's Contracture in the Australian Health System.澳大利亚医疗体系中溶组织梭状芽孢杆菌胶原酶与筋膜切除术治疗掌腱膜挛缩症的成本比较
J Hand Surg Asian Pac Vol. 2018 Sep;23(3):336-341. doi: 10.1142/S2424835518500327.
6
Minimally invasive options in Dupuytren's contracture: aponeurotomy, enzymes, stretching, and fat grafting.掌腱膜挛缩症的微创选择:切开术、酶、伸展和脂肪移植。
Plast Reconstr Surg. 2014 Nov;134(5):822e-829e. doi: 10.1097/PRS.0000000000000603.
7
Dupuytren's Contracture: Approach to Treatment and Counseling Patients in 2024.掌腱膜挛缩症:2024 年治疗方法及患者咨询建议
Clin Plast Surg. 2024 Oct;51(4):527-537. doi: 10.1016/j.cps.2024.05.002. Epub 2024 Jun 22.
8
[Dupuytren's disease - patient satisfaction and functional results one year after partial fasciectomy and injection of collagenase].[掌腱膜挛缩症——部分筋膜切除术及注射胶原酶一年后的患者满意度和功能结果]
Handchir Mikrochir Plast Chir. 2013 Oct;45(5):258-64. doi: 10.1055/s-0033-1351329. Epub 2013 Oct 2.
9
[Collagenase-A revolution of Dupuytren's therapy].[胶原酶——掌腱膜挛缩症治疗的一场革命]
Ther Umsch. 2014 Jul;71(7):379-84. doi: 10.1024/0040-5930/a000526.
10
Dupuytren's disease.杜普伊特伦挛缩病
Orthopedics. 2012 Jan;35(1):52-60. doi: 10.3928/01477447-20111122-23.

引用本文的文献

1
Surgical and Injection Interventions for Dupuytren's Disease: A Systematic Review Protocol.掌腱膜挛缩症的手术和注射干预:一项系统评价方案
Rev Bras Ortop (Sao Paulo). 2025 Sep 8;60(3):s00451811595. doi: 10.1055/s-0045-1811595. eCollection 2025 Jun.
2
Therapy for Dupuytren's Disease (II): Collagenase Therapy vs. Limited Fasciectomy-A Long-Term Comparative Study.掌腱膜挛缩症的治疗(II):胶原酶治疗与有限筋膜切除术——一项长期对比研究。
Life (Basel). 2025 Jan 10;15(1):76. doi: 10.3390/life15010076.
3
Ledderhose's Disease: An Up-to-Date Review of a Rare Non-Malignant Disorder.
莱德霍斯病:一种罕见的非恶性疾病的最新综述
Clin Pract. 2023 Sep 28;13(5):1182-1195. doi: 10.3390/clinpract13050106.
4
Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies.《掌腱膜挛缩症的药物治疗:当前和新策略》。
J Hand Surg Am. 2023 Aug;48(8):810-821. doi: 10.1016/j.jhsa.2023.02.003. Epub 2023 Mar 17.
5
Acute Pain Intensity After Collagenase Injection in Patients With Dupuytren Contracture.掌腱膜挛缩症患者注射胶原酶后的急性疼痛强度
J Hand Surg Glob Online. 2019 Nov 27;2(1):16-20. doi: 10.1016/j.jhsg.2019.10.004. eCollection 2020 Jan.
6
Sorafenib in Dupuytren and Ledderhose Disease.索拉非尼治疗掌腱膜挛缩症和足底筋膜炎。
Oncologist. 2022 Mar 11;27(3):e294-e296. doi: 10.1093/oncolo/oyab050.
7
Treatment Options for Dupuytren's Disease: Tips and Tricks.掌腱膜挛缩症的治疗选择:技巧与窍门
Plast Reconstr Surg Glob Open. 2022 Jan 27;10(1):e4046. doi: 10.1097/GOX.0000000000004046. eCollection 2022 Jan.
8
Initial Treatment Choice Affects Cost-Effectiveness and Reintervention Rates for Dupuytren Contracture: A National Census Among Veterans Affairs Patients.初始治疗选择会影响掌腱膜挛缩患者的成本效益和再干预率:一项针对退伍军人事务部患者的全国普查。
Hand (N Y). 2023 Jul;18(5):885-890. doi: 10.1177/15589447211072251. Epub 2022 Jan 29.
9
Dupuytren's Disease: An Outcomes-Focused Update.掌腱膜挛缩症:以结果为导向的最新进展
Semin Plast Surg. 2021 Aug;35(3):216-222. doi: 10.1055/s-0041-1731631. Epub 2021 Jul 6.
10
Dupuytren's disease: using needles more across the world.掌腱膜挛缩症:全球更多地使用针具。
J Hand Surg Eur Vol. 2022 Jan;47(1):80-88. doi: 10.1177/17531934211043307. Epub 2021 Sep 9.